Anna Protopapas's most recent trade in Nuvalent Inc - Ordinary Shares - Class A was a trade of 4,147 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nuvalent Inc - Ordinary Sh... | Anna Protopapas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 4,147 | 4,147 | - | - | Stock Option (Right to Buy) | |
| Nuvalent Inc - Ordinary Sh... | Anna Protopapas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 2,647 | 5,146 | - | 0 | Class A Common Stock | |
| Mersana Therapeutics Inc | Anna Protopapas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 61,500 | 61,500 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | Anna Protopapas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 21,250 | 176,678 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Anna Protopapas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 21,250 | 0 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Anna Protopapas | Director | Sale of securities on an exchange or to another person at price $ 0.58 per share. | 15 Jan 2025 | 8,637 | 168,041 (0%) | 0% | 0.6 | 5,009 | Common Stock |
| Mersana Therapeutics Inc | Anna Protopapas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2025 | 16,750 | 16,750 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Anna Protopapas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2025 | 16,750 | 161,619 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Anna Protopapas | Director | Sale of securities on an exchange or to another person at price $ 0.63 per share. | 14 Jan 2025 | 6,191 | 155,428 (0%) | 0% | 0.6 | 3,900 | Common Stock |
| Mersana Therapeutics Inc | Anna Protopapas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 31,250 | 62,500 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Anna Protopapas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 31,250 | 156,403 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Anna Protopapas | Director | Sale of securities on an exchange or to another person at price $ 0.66 per share. | 13 Jan 2025 | 11,534 | 144,869 (0%) | 0% | 0.7 | 7,612 | Common Stock |
| Nuvalent Inc - Ordinary Sh... | Anna Protopapas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 3,789 | 3,789 | - | - | Stock Option (Right to Buy) | |
| Nuvalent Inc - Ordinary Sh... | Anna Protopapas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 2,499 | 2,499 | - | 0 | Class A Common Stock | |
| Mersana Therapeutics Inc | Anna Protopapas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | Protopapas Anna | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 31,250 | 98,844 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Anna Protopapas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 31,250 | 93,750 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Protopapas Anna | Director | Sale of securities on an exchange or to another person at price $ 2.71 per share. | 13 Jan 2024 | 29,399 | 125,153 (0%) | 0% | 2.7 | 79,671 | Common Stock |
| Mersana Therapeutics Inc | Protopapas Anna | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 21,250 | 136,844 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Protopapas Anna | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 21,250 | 21,250 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Protopapas Anna | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 17,708 | 0 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Anna Protopapas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 17,708 | 154,552 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Anna Protopapas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 16,750 | 115,594 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Anna Protopapas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 16,750 | 33,500 | - | - | Restricted Stock Unit | |
| Nuvalent Inc - Ordinary Sh... | Protopapas Anna | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2023 | 5,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Nuvalent Inc - Ordinary Sh... | Anna Protopapas | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.36 per share. | 18 Dec 2023 | 5,000 | 5,000 | - | 9.4 | 46,800 | Class A Common Stock |
| Nuvalent Inc - Ordinary Sh... | Protopapas Anna | Director | Sale of securities on an exchange or to another person at price $ 75.67 per share. | 18 Dec 2023 | 5,000 | 0 | - | 75.7 | 378,350 | Class A Common Stock |
| Nuvalent Inc - Ordinary Sh... | Anna Protopapas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2023 | 562,500 | 562,500 | - | - | Stock option (right to buy) | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Jan 2023 | 240,244 | 10,371 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Jan 2023 | 240,244 | 240,244 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2023 | 125,000 | 125,000 | - | - | Restricted stock unit | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 21,250 | 48,371 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 21,250 | 42,500 | - | - | Restricted stock unit | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 17,708 | 66,079 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 17,708 | 17,708 | - | - | Restricted stock unit | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.74 per share. | 13 Jan 2023 | 17,346 | 48,733 (0%) | 0% | 5.7 | 99,566 | Common Stock |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 16,750 | 27,121 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 16,750 | 50,250 | - | - | Restricted stock unit | |
| Nuvalent Inc - Ordinary Sh... | Anna Protopapas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Nuvalent Inc - Ordinary Sh... | Anna Protopapas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 301,450 | 301,450 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 67,000 | 67,000 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 38,958 | 322,878 (0%) | 0% | - | Common Stock | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 21,250 | 63,750 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 17,708 | 35,416 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 100,000 | 0 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 100,000 | 324,922 (0%) | 0% | - | Common Stock | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 12.02 per share. | 15 Jul 2021 | 21,901 | 282,978 (0%) | 0% | 12.0 | 263,250 | Common Stock |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 12.47 per share. | 15 Jul 2021 | 20,043 | 304,879 (0%) | 0% | 12.5 | 249,936 | Common Stock |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 382,500 | 382,500 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 85,000 | 85,000 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 17,709 | 230,120 (0%) | 0% | - | Common Stock | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 17,709 | 53,124 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | Anna Protopapas | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.09 per share. | 15 Jan 2021 | 5,198 | 224,922 (0%) | 0% | 21.1 | 109,626 | Common Stock |